SUNNYVALE, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share. 1,923,076 shares in the offering were offered for sale by Silk Road Medical, and 4,885,078 million shares were offered for sale by certain selling securityholders. Gross proceeds from the offering to Silk Road Medical were approximately $75 million. The selling stockholders granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. Silk Road Medical did not receive proceeds from the sale of its common stock by the selling securityholders.
J.P. Morgan and BofA Securities acted as joint book-running managers of the offering. Citigroup also acted as book-running manager. Stifel acted as co-manager.
Read More: https://www.globenewswire.com/news-release/2020/05/08/2030564/0/en/Silk-Road-Medical-Announces-Closing-of-Follow-on-Public-Offering.html
Via: GlobeNewsWire Via: PR Newswire SAN JOSE, Calif., May 7, 2020 /PRNewswire/ -- Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced along with the U.S. Department of Health and Human Services (HHS) and in collaboration with the New York State Department of Health that they have deployed 50 Tablo™ Hemodialysis Systems to hospitals in New York City and Long Island. The first five locations include Long Island Jewish Medical Center, North Shore University Hospital, Mount Sinai South Nassau, Staten Island University Hospital – North, and Brooklyn Hospital Center - Downtown Campus. Five additional hospitals in NYC are also expected to receive Tablo systems in the near term as part of this deployment. Via: GlobeNewsWire SUNNYVALE, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share, before deducting underwriting discounts and commissions. 1,923,076 shares in the offering are being offered for sale by Silk Road Medical, and 4,885,078 shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders have granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road are expected to be approximately $75 million. Silk Road Medical will not receive proceeds from the sale of its common stock by selling securityholders. The offering is expected to close on May 8, 2020, subject to the satisfaction of customary closing conditions. Via: GlobeNewsWire SUNNYVALE, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of $100 million of shares of its common stock. $75 million of the shares in the offering are being offered for sale by Silk Road Medical and $25 million of the shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders expect to grant the underwriters a 30-day option to purchase up to an additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Via: GlobeNewsWire SUNNYVALE, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2020. Via: Silk Road Medical SUNNYVALE, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today provided a corporate update in response to the COVID-19 pandemic. Via: GlobeNewsWire SUNNYVALE, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today that effective as of market open on March 6, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "SILK". Via: 2 Minute Medicine 1. In patients receiving carotid stenosis treatment, transcarotid artery revascularization was associated with a significantly lower risk of stroke or death compared to transfemoral carotid artery stenting. Via: PR Newswire Financing to Support Commercial Acceleration of the Tablo® Hemodialysis System, an Enterprise Solution Designed to Reduce the Cost and Complexity of Dialysis Via: TechCrunch Hinge Health, the San Francisco-based startup that offers a digital solution to treat chronic musculoskeletal (MSK) conditions — such as back and joint pain — has closed a $90 million Series C. |
Archives
October 2023
|